Fatigue in multiple sclerosis.

被引:76
作者
Krupp L.B. [1 ]
Christodoulou C. [1 ]
机构
[1] Department of Neurology, State University of New York at Stony Brook, HSC-T12-020, Stony Brook, 11794-8121, NY
基金
美国国家卫生研究院;
关键词
Multiple Sclerosis; Multiple Sclerosis Patient; Chronic Fatigue Syndrome; Amantadine; Modafinil;
D O I
10.1007/s11910-001-0033-7
中图分类号
学科分类号
摘要
Fatigue is among the most common, yet least understood, symptoms of multiple sclerosis (MS) [1.]. It can profoundly disrupt the occupational and social functioning of patients, and is recognized as a criterion for MS disability by the Social Security Administration. Most approaches to fatigue assessment can be classified as either self-report scales or performance-based measures of motor or cognitive output. During the clinical management of fatigue, it is important to consider the role of other MS symptoms on fatigue, as well as that of non-MS-related medical conditions. Management of fatigue in MS often entails both pharmacologic and behavioral components. This article reviews recent developments in the assessment, treatment, and pathogenesis of MS fatigue.
引用
收藏
页码:294 / 298
页数:4
相关论文
共 137 条
[51]  
Jason LA(undefined)undefined undefined undefined undefined-undefined
[52]  
Torres A(undefined)undefined undefined undefined undefined-undefined
[53]  
Schwid S(undefined)undefined undefined undefined undefined-undefined
[54]  
Thornton C(undefined)undefined undefined undefined undefined-undefined
[55]  
Pandya S(undefined)undefined undefined undefined undefined-undefined
[56]  
Djaldetti R(undefined)undefined undefined undefined undefined-undefined
[57]  
Ziv I(undefined)undefined undefined undefined undefined-undefined
[58]  
Achiron A(undefined)undefined undefined undefined undefined-undefined
[59]  
Melamed E(undefined)undefined undefined undefined undefined-undefined
[60]  
Sharma K(undefined)undefined undefined undefined undefined-undefined